CNR1 Knockout U251 MG Cell Line

The choice depends on whether you are studying CNR1 (cannabinoid receptor 1, CB1)'s role as the principal CNS cannabinoid receptor or modeling its functions in glioblastoma and cannabinoid pharmacology. The Knockout line is the standard tool for asking whether CB1 is required for these processes — CNR1 is a Gαi/o-coupled seven-transmembrane GPCR activated by endocannabinoids (anandamide/AEA, 2-arachidonoylglycerol/2-AG) and exocannabinoids (Δ⁹-THC, synthetic cannabinoids), with the highest CNS GPCR expression and roles in synaptic plasticity, pain, appetite, anxiety, and energy metabolism. Overexpression is useful for studying CB1 in heterologous expression contexts. For neuro-oncology and cannabinoid pharmacology research, the EDITGENE CNR1 Knockout in U251 MG is uniquely valuable — U251 MG is a glioblastoma cell line, and CB1 has been characterized in glioblastoma biology with reported antitumor effects of cannabinoid agonists; cannabinoid therapy has been explored for GBM. CNR2 (CB2) paralog expression analysis aids interpretation. Rescue with wild-type or signaling-deficient CB1 enables structure-function studies. The knockout is a critical specificity tool for ⭐ rimonabant (Acomplia, withdrawn anti-obesity CB1 inverse agonist due to depression/suicide risks), Δ⁹-THC, nabilone, dronabinol (FDA-approved cannabinoids for chemotherapy-induced nausea, AIDS-related anorexia), and emerging CB1-targeted therapeutics.

Primary applications: • CB1 signaling: cAMP suppression (Gαi/o), Ca²⁺ mobilization, ERK activation following WIN55,212-2, CP55,940, anandamide, 2-AG, or Δ⁹-THC stimulation in CB1-null cells. • Glioblastoma biology: in U251 GBM context, characterization of cannabinoid agonist anti-tumor effects given the reported cannabinoid antitumor activity. • Rimonabant specificity: critical genetic control for rimonabant (withdrawn CB1 inverse agonist) — should have no effect in CB1-null cells. • Δ⁹-THC and synthetic cannabinoid specificity: cannabis-derived and synthetic cannabinoid binding/signaling specificity testing. • Biased agonism studies: G-protein versus β-arrestin biased cannabinoid ligands. EDITGENE recommends this U251 MG-based model for researchers investigating GBM cannabinoid pharmacology, CNS cannabinoid biology, and emerging CB1-targeted therapeutics.

Yes. CB1 rescue experiments are well-established for cannabinoid pharmacology research: • Construct design: use a codon-modified CNR1 sequence with a small intracellular C-terminal tag (FLAG, HA). CB1 is a seven-transmembrane GPCR with N-terminal extracellular region, transmembrane bundle, and C-terminal intracellular tail — preserve all elements; note that C-terminal tags may affect β-arrestin recruitment. • Surface localization validation: confirm plasma membrane localization before cannabinoid binding studies. • Signaling-deficient rescue: DRY motif mutations disrupt Gαi/o coupling. • Biased agonism studies: specific mutations can generate G-protein-biased or β-arrestin-biased CB1 variants. • Functional readout: rescue should restore cannabinoid-induced cAMP suppression and ERK activation. U251 MG-specific considerations: • U251 MG is a human glioblastoma multiforme (GBM) cell line — one of the principal continuous GBM models for neuro-oncology, BBB research, and cannabinoid pharmacology in glial-derived cancer context. • Lentiviral transduction is supported with moderate efficiency. • U251 MG retains key GBM features and is widely used for studying brain tumor biology and CNS pharmacology.